natgillin/translations-raw huggingface dataset:
30 mg tablet: blue, round, with “OTSUKA” and “30” on one side.
30-mg tableta: modra, okrogla z vtisnjenim napisom "OTSUKA" in "30" na eni strani.
30 mg tablets: - Carton box with 20 or 100 tablets in PVC/aluminium heat sealed blisters 150 mg tablets: - Carton box with 10, 20 or 100 tablets in PVC/aluminium heat sealed blisters
Tablete 30 mg: - zloženka z 20 ali s 100 tabletami v zavarjenih pretisnih omotih iz pvc in aluminija Tablete 150 mg: - zloženka z 10, 20 ali s 100 tabletami v zavarjenih pretisnih omotih iz pvc in
30 mg weekly
30 mg na teden
30 mg) once a day.
30 mg) enkrat na dan.
30 mg) than that recommended in the treatment of MS.
30 mg), kot so priporočeni za zdravljenje MS.
30 mg/50 mg Weekly
30 mg/50 mg na teden
30 mg/50 mg Weekly + Metformin
30 mg/50 mg na teden + metformin
30 mg/kg twice daily
30 mg/kg dvakrat na dan
30 mg: Round and pink, marked with "A" over "643" on one side and "30" on the other.
Okrogle oblike in roza barve, označene z "A" nad "643" na eni strani in 30 na drugi.
30 micrograms interferon beta-1a
30 mikrogramov interferona beta-1a
30 micrograms PRE-FILLED SYRINGES LABEL
NALEPKA ZA NAPOLNJENO INJEKCIJSKO BRIZGO 30 mikrogramov
30 micrograms/0.3 ml solution for injection in pre-filled syringe 40 micrograms/0.3 ml solution for injection in pre-filled syringe 50 micrograms/0.3 ml solution for injection in pre-filled syringe 60 micrograms/0.3 ml solution for injection in pre-filled syringe 75 micrograms/0.3 ml solution for injection in pre-filled syringe 100 micrograms/0.3 ml solution for injection in pre-filled syringe 120 micrograms/0.3 ml solution for injection in pre-filled syringe 150 micrograms/0.3 ml solution for injection in pre-filled syringe 200 micrograms/0.3 ml solution for injection in pre-filled syringe 250 micrograms/0.3 ml solution for injection in pre-filled syringe 360 micrograms/0.6 ml solution for injection in pre-filled syringe
30 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 40 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 50 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 60 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 75 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 100 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 120 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 150 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 200 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 250 mikrogramov/0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 360 mikrogramov/0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
30 million IU
30 milijonov i.e.
30 million IU in doses ranging from 2.5 to 10 million IU.
30 milijonov i.e., lahko odmerjamo v razponu od 2,5 do 10 milijonov i.e.
30 million IU solution for injection in multidose pen 1 pen, 12 injection needles and 12 cleansing swabs 2 pens, 24 injection needles and 24 cleansing swabs 8 pens, 96 injection needles and 96 cleansing swabs
30 milijonov i.e. raztopina za injiciranje v večodmernem peresniku 1 peresnik, 12 injekcijskih igel in 12 čistilnih tamponov 2 peresnika, 24 injekcijskih igel in 24 čistilnih tamponov 8 peresnikov, 96 injekcijskih igel in 96 čistilnih tamponov
30 million IU solution for injection multidose pen 1 pen, 12 injection needles and 12 cleansing swabs
30 milijonov i.e. raztopina za injiciranje v večodmernem peresniku 1 peresnik, 12 injekcijskih igel in 12 čistilnih tamponov
30 million IU/pen
30 milijonov i.e./peresnik
30 minute infusion in healthy subjects.
apiksaban n = 9.120
30 minutes after the test solution has been taken (point 5), the “30-minute-value” sample is collected in the breath bag, which remains in the pack (labelled “sampling time: 30-minute- value”) as described under point 2.
30 minut po zaužitju testne raztopine (korak 5) zberite vzorec "30-minutne vrednosti" v dihalni vrečki, ki še ostane v kompletu (z napisom "čas vzorčenja: 30-minutna vrednost"), kot je opisano v koraku 2.
30 minutes after the test solution has been taken (point 6), the “30-minute-value” samples are collected in both containers, which remain in the pack (labelled “sampling time: 30-minute- value”) as described under points 2 and 3.
30 minut po zaužitju testne raztopine (korak 6) zberite vzorca "30-minutne vrednosti" v epruveti, ki sta še ostali v kompletu (z napisom "čas vzorčenja: 30-minutna vrednost"), kot je opisano v korakih 2 in 3.
30 minutes after the test solution has been taken (point 7), the “30-minute-value” samples are collected in the breath sample containers labelled “sampling time: 30-minute-value” as described under point 3 and 4.
30 minut po zaužitju testne raztopine (korak 7) zberite vzorca "30-minutne vrednosti" v vsebniku za vzorec dihanja (z napisom "čas vzorčenja: 30-minutna vrednost"), kot je opisano v korakih 3 in 4.
30 minutes of taking Eurartesim, the whole dose must be taken again.
30 minut po uporabi zdravila Eurartesim, je treba ponovno vzeti ves odmerek;
30 MIU (300 µg/0.5
30 MIU (300 µg/0,5
30 MIU (300 µg/0.5 ml)
30 MIU (300 µg/0,5 ml)
30 ml and 50 ml bottle
30 ml in 50 ml steklenička
30 ml bottle
30 ml plastenka
30 ml bottle containing 30 Masivet 50 mg film-coated tablets.
30 ml steklenička vsebuje 30 filmsko obloženih tablet Masivet 50 mg.
30 ml clear Type I glass vial with rubber stopper and aluminium cap with plastic seal.
30-ml viala, izdelana iz stekla tipa I, z gumijastim zamaškom in aluminijasto zaporko s plastičnim pečatom.
30 ml glass mixing tube with cap.
30 ml stekleno epruveto za mešanje z zaporko,
30 ml HDPE bottles with induction-sealed, polypropylene child-resistant caps; 20 film-coated tablets per bottle.
30 ml vsebnik iz HDPE z indukcijsko zavarjeno, polipropilensko, za otroke varno zaporko; 20 filmsko obloženih tablet v vsebniku.
30 ml mixing and administration vial. glass, with cap
30 ml prebodno stekleničko za mešanje in aplikacijo z zaporko.
30 ml plastic bottles capped with child-resistant induction seal closure; 20 film-coated tablets per bottle.
30 ml plastični vsebnik z indukcijsko zavarjeno zaporko, varno za otroke; 20 filmsko obloženih tablet v vsebniku.
30 mL Type 1 glass vial with an elastomeric closure and an aluminium seal with a flip-off button containing 400 mg of siltuximab.
30 ml viala iz stekla tipa 1 z elastomernim zamaškom in neprodušno aluminijasto zaporo s snemno zaporko, ki vsebuje 400 mg siltuksimaba.
30 mL Type 1 glass vial with an elastomeric stopper (butyl rubber with an inert polymer coating on the product contact surface and lubricant on the top surface for easier machinability) and aluminium seal with flip-off cap.
30 ml steklena viala iz stekla tipa I z elastomernim zamaškom (butilna guma prevlečena s polimerno plastjo na stični površini izdelka in mazivom na zgornji površini za lažjo strojno obdelavo) in aluminijsko zaporo s snemljivo zaporko.
30 mL type I clear glass vial, closed with fluoropolymer laminated elastomeric stopper and aluminium seal with an orange plastic flip off cap.
30 ml prozorna viala iz stekla tipa I, zaprta s fluoropolimerno laminiranim elastomernim zamaškom in aluminijasto zaporo z oranžno plastično snemno zaporko.
30 ml) once a day.
30 ml) enkrat na dan.
30 months
30 mesecev.
30 months
30 mánuðir
30 MU (300 µg/0.5 ml)
30 ME (300
30 MU (300 µg/0.5 ml)
48 ME (480
30 MU (60 MU/ml)
(60 ME/ml)
30 MU(60 MU/ml)
(60 ME/ml)
30 MU/0.5 ml
30 M e./0,5 ml
30 orodispersible tablets
30 orodisperzibilnih tablet
30 pack - No special requirements for storage 90 pack - No special requirements for storage
Pakiranje z 90 vsebniki – za shranjevanje niso potrebna posebna navodila.
30 patches
30 transdermalnih obližev
30 pipettes
30 merilnih kapalk
30 pre-filled syringes
napolnjena
30 pre-filled syringes
napolnjenih
30 prolonged-release hard capsules 30×1 prolonged-release hard capsules 50 prolonged-release hard capsules 50×1 prolonged-release hard capsules 100 prolonged-release hard capsules 1001 prolonged-release hard capsules
30 trdih kapsul s podaljšanim sproščanjem 30×1 trdih kapsul s podaljšanim sproščanjem 50 trdih kapsul s podaljšanim sproščanjem 50×1 trdih kapsul s podaljšanim sproščanjem 100 trdih kapsul s podaljšanim sproščanjem 100×1 trdih kapsul s podaljšanim sproščanjem
30 prolonged-release tablets - EU/1/07/395/059 350 prolonged-release tablets - EU/1/07/395/060
30 tablet s podaljšanim sproščanjem s - EU/1/07/395/059 350 tablet s podaljšanim sproščanjem - EU/1/07/395/060
30 prolonged-release tablets - EU/1/07/395/061 350 prolonged-release tablets - EU/1/07/395/062
30 tablet s podaljšanim sproščanje - EU/1/07/395/061 350 tablet s podaljšanim sproščanje - EU/1/07/395/062
30 prolonged-release tablets - EU/1/07/395/094 350 prolonged-release tablets - EU/1/07/395/095
30 tablet s podaljšanim sproščanjem - EU/1/07/395/094 350 tablet s podaljšanim sproščanjem - EU/1/07/395/095
30 sachets
30 vrečk
30 sachets +
30 vrečic +
30 sachets and 1 mixing bottle + 1 oral syringe
30 vrečic in 1 mešalna plastenka + 1 brizga za peroralno odmerjanje
30 sachets of 1 gram.
30 vrečic po 1 gram
30 sachets of powder for oral suspension
30 vrečic praška za peroralno suspenzijo
30 sachets, powder for oral suspension in sachet 60 sachets, powder for oral suspension in sachet 90 sachets, powder for oral suspension in sachet
30 vrečk, prašek za peroralno suspenzijo v vrečki 60 vrečk, prašek za peroralno suspenzijo v vrečki 90 vrečk, prašek za peroralno suspenzijo v vrečki
30 September
30. september
30 single-dose containers
30 enoodmernih
30 single-dose containers
30 enoodmernih vsebnikov
30 soft capsules
30 mehkih kapsul
30 sprays
30 vpihov
30 tablets
(PVC/alu)
30 tablets
130 tablet
30 tablets
200 tablet
30 tablets
30 %.
30 tablets
6 x 30 tablet
30 tablets
EU/1/11/706/020
30 tablets (PVC/PCTFE blisters)
30 tablet (PVC/PCTFE pretisni omoti)
30 tablets 100 tablets
30 tablet 100 tablet
30 tablets 7 tablets
30 tablet 7 tablet
30 tablets: EU/1/08/469/002
30 tablet: EU/1/08/469/002
30 tablets: EU/1/08/469/007
30 tablet: EU/1/08/469/007
30 tablets: EU/1/08/469/012
30 tablet: EU/1/08/469/012
30 tablets: EU/1/08/469/017
30 tablet: EU/1/08/469/017
30 tablets: EU/1/08/469/022
30 tablet: EU/1/08/469/022
30 tablets: EU/1/08/480/019
30 tablet: EU/1/08/480/019
30 tablets: EU/1/09/579/001
30 tablet: EU/1/09/579/001
30 tablets: EU/1/09/579/007
30 tablet: EU/1/09/579/007
30 tablets: EU/1/09/579/013
30 tablet: EU/1/09/579/013
30 tablets: EU/1/10/632/003
30 tablet: EU/1/10/632/003
30 tablets: EU/1/10/632/010
30 tablet: EU/1/10/632/010
30 tablets: EU/1/10/632/017
30 tablet: EU/1/10/632/017
30 tablets: EU/1/11/721/003
30 tablet: EU/1/11/721/003
30 tablets: EU/1/11/721/010
30 tablet: EU/1/11/721/010
30 tablets: EU/1/11/721/017
30 tablet: EU/1/11/721/017
30 tablets: EU/1/11/723/003
30 tablet: EU/1/11/723/003
30 tablets: EU/1/11/723/010
30 tablet: EU/1/11/723/010
30 tablets: EU/1/11/723/017
30 tablet: EU/1/11/723/017
30 to 39.9 kg
30 do 39,9 kg
30 to <40 kg
30 do < 40 kg
30 to<50
30 až < 50
30 transdermal patches
30 transdermalnih obližev
30 unit doses
30 odmerkov
30 vials +
30 vial + 30
30 vials +
injiciranje
30 vials of powder
30 vial s praškom
30 x (10 capsules +
30 x (10 kapsul +
30 x 1 (Unit dose)
30 x 1 (enoodmerno pakiranje)
30 x 1 blisters (1 pouch)
30 x 1 pretisni omot
30 x 1 blisters (1 pouch)
30 x 1 pretisni omot (vrečka)
30 x 1 capsule (unit dose)
30 x 1 kapsula (z razdelki za posamezni odmerek)
30 x 1 capsules
30 x 1 kapsul
30 x 1 capsules (unit dose)
30 x 1 kapsul (posamezni odmerek)
30 x 1 capsules (unit dose) + 1 inhaler
30 x 1 kapsula (enkratni odmerek) + 1 inhalator
30 x 1 chewable tablets
30 x 1 žvečljiva tableta
30 x 1 chewable tablets.
30 x 1 žvečljiva tableta
30 x 1 film-coated tablet; 3 blister cards of 10 x 1 film-coated tablet each in Alu/Alu perforated unit dose blisters, or
30 x 1 filmsko obloženo tableto v 3 perforiranih enoodmernih pretisnih omotih (Alu/Alu), ali
30 x 1 film-coated tablets
30 x 1 filmsko obloženih tablet
30 x 1 film-coated-tablets
30 x 1 filmsko obložena tableta
30 x 1 hard gastro-resistant capsules
30 x 1 trda gastrorezistentna kapsula
30 x 1 orodispersible tablet
30 x 1 orodisperzibilna tableta
30 x 1 orodispersible tablet:EU/1/09/525/028
30 x 1 orodisperzibilna tableta: EU/1/09/525/028
30 x 1 orodispersible tablet:EU/1/09/525/033
30 x 1 orodisperzibilna tableta: EU/1/09/525/033
30 x 1 orodispersible tablet:EU/1/09/525/038
30 x 1 orodisperzibilna tableta: EU/1/09/525/038
30 x 1 orodispersible tablet:EU/1/09/525/043
30 x 1 orodisperzibilna tableta: EU/1/09/525/043
30 x 1 soft capsules in Aluminium/aluminium perforated unit dose blisters
30 x 1 mehka kapsula v perforiranem enoodmernem pretisnem omotu aluminij/aluminij
30 x 1 soft capsules in Aluminium/aluminium perforated unit dose blisters
30 x 1 mehka kapsula v perforiranih enoodmernih pretisnih omotih aluminij/aluminij
30 x 1 tablet
100 x 1 tablet
30 x 1 tablet
30x1 tablet
30 x 1 tablet (unit
30 x 1 tableta (enkratno
30 x 1 tablet (unit
40 x 1 tableta (enkratno
30 x 1 tablet (unit dose)
30 x 1 tableta (enkratno odmerjanje)
30 x 1 tablet (unit dose)
30 x 1 tableta (za enkratni odmerek)
30 x 1 TABLETS
30 x 1 TABLET
30 x 1 tablets
30x1 tablet
30 x 1 tablets
tableta
30 x 1 tablets (unit dose)
30 tablet
30 x 1 tablets (unit dose)
30 x 1 tablet (enoodmernih pretisnih)
30 x 1 tablets (unit dose)
30 x 1 tableta (enkratni
30 x 1 tablets (unit dose)
30 x 1 tableta (enkratni odmerek)
30 x 1 tablets (unit dose)
30 x 1 tableta (enoodmerni pretisni omoti)
30 x 1 tablets (unit dose)
30 x 1 tableta (posamezni odmerek)
30 x 1 tablets in PVC/aluminium perforated unit dose blister.
30 x 1 tablete v perforiranem pretisnem omotu za enkratni odmerek PVC/aluminij.
30 ≤ and < 50
30 ≤ in < 50
30 g (6 million IU)
30 g (6 milijonov i.e.)
30 g/0.5 ml (6 million IU)
30 g/0,5 ml (6 milijonov i.e.)
30 g/0.5ml (6 million IU)
30 g/0,5ml (6 milijonov i.e.)
30% dissolved insulin, 70% crystalline protamine insulin
30 % raztopljenega insulina, 75 % kristalnega protamin insulina
30% soluble insulin aspart and 70% insulin aspart crystallised with protamine
30 % topnega insulina aspart in 70 % insulina aspart, kristaliziranega s protaminom
30% soluble insulin aspart and 70% insulin aspart crystallised with protamine
30 % topnega insulina aspart in 70 % s protaminom kristaliziranega insulina aspart
30% to 60% (IU/dl).
30 - 60 % (i.e./dl).
30% to 60% (IU/dl).
na 30 do 60 % (i.e./dl).
30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 2 remaining free of specific skin lesions.
30) cepljenih prašičev, kar prav tako pomeni, da se pri njih niso pojavile specifične kožne lezije.
30, 42, 50, 56, 98, 100, 112 and multipacks containing 840 (20 x 42), 980 (10 x 98) or 1000 (20 x 50) tablets are presented.
42, 50, 56, 98, 100, 112 tablet in večkratna pakiranja po 840 (20 x 42), 980 (10 x 98), 1000 (20 x 50) tablet.
30, 42, 50, 56, 98, 100, 112, and multipacks containing 840 (20 x 42), 980 (10 x 98) or 1000 (20 x 50) tablets are presented.
42, 50, 56, 98, 100, 112 tablet in večkratna pakiranja po 840 (20 x 42), 980 (10 x 98), 1000 (20 x 50) tablet.
30, 50 or 100 tablets.
20, 21, 30, 50 ali 100 tablet.
30, 60 or 90 sachets per carton.
30, 60 ali 90 vrečic na škatlo.
30,000 IU/0.75 ml
30.000 i.e./0,75 ml
30-100 IU/kg
30–100 i.e./kg
30-100 IU/kg.
30-100 i.e./kg.
30-36 Avenue Gustave Eiffel 37100 Tours - France
30-36 Avenue Gustave Eiffel 37100 Tours - Francija
30-36 Avenue Gustave Eiffel, BP 7166 F-37071 Tours Cedex 2 - France
30-36 Avenue Gustave Eiffel, BP 7166 F-37071 Tours Cedex 2 - Francija
30-36, avenue Gustave Eiffel – BP 27166 F-37071 Tours Cedex 2
30–36, avenue Gustave Eiffel – BP 27166 F-37071 Tours Cedex 2
30-39 3.0 mg* zoledronic acid
30-39 3,0 mg* zoledronske kisline
30-60 Every 24 hours, at least 1 day, until healing is achieved.
Vsakih 24 ur vsaj 1 dan, dokler se rana ne zaceli.
30-60 Every 24 hours, at least 1 day,until healing is achieved
30-60 Na 24 ur, vsaj 1 dan, dokler ni doseženo celjenje.
30-60 Repeat infusion every 12-24 hours for 3-4 days or more until pain and acute disability are resolved
30-60 Infuzijo ponavljajte na 12 do 24 ur 3 do 4 dni ali več, dokler bolečina in akutna prizadetost ne mineta.
30-60 Repeat infusion every 12-24 hours for 3-4 days or more until pain and acute disability are resolved.
30–60 Infuzijo ponovimo vsakih 12–24 ur, 3–4 dni ali dokler bolečina oziroma akutna nezmožnost ne izzvenita.
30-90 mins
30-90 min
30-<50
30 až < 50
30-day
30 dni
30-gauge needle alcohol wipes
iglo velikosti 30 alkoholne blazinice
30-gauge needles for injecting your medicine
igle velikosti 30 za injiciranje zdravila alkoholne blazinice
30-minute-value”), as described under steps 3 to 4.
Čas vzorčenja: 30-minutna vrednost"), kot je opisano v korakih 3 in 4.
30-minute-value”), as described under steps 3 to 4.
Čas vzorčenja: 30-minutna vrednost”), kot je opisano v korakih 3 in 4.
30-Week Study
30-tedenska študija
30.9 to 34.4
30,9 do 34,4
30/10/2016
30. oktober 2016
30/10/2017
30. oktober 2016
30/11/2015 (aligned with
30/11/2015 (skladno s časom
300 (10 x 30) ampoules (multipack)
300 (10 x 30) ampul (večkratno pakiranje)
300 (10 x 30) AMPOULES WITH 2 ML
300 (10 x 30) AMPUL Z 2 ML
300 (10x30) tablets (multipack)
300 (10x30) tablet (skupno pakiranje)
300 (3 x 100 mg or 6 x 50 mg)
300 (3 x 100 mg ali 6 x 50 mg)
300 - 500 mg/day (once a day)
300 – 500 mg/dan (enkrat na dan)
300 ampoules
300 ampul
300 AMPOULES WITH 2 ML
300 AMPUL Z 2 ML
300 ampoules.
300 ampul.
300 Capsules
300 kapsul
300 copies/ml to
300 kopij/ml do
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikih z adenokarcinomom ţelodca (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so dobivali docetaksel v kombinaciji s cisplatinom in 5 -fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neţeleni učinki);
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikih z adenokarcinomom želodca (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so dobivali docetaksel v kombinaciji s cisplatinom in 5 -fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki);
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikih z adenokarcinomom želodca (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so prejemali docetaksel v kombinaciji s cisplatinom in 5 fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikih z adenokarcinomom želodca (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikih z adenokarcinomom želodca (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (predstavljeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikov z adenokarcinomom želodca (221 bolnikov v III. fazi študije in 79 bolnikov v
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
300 bolnikov z adenokarcinomom želodca (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so prejemali docetaksel v kombinaciji s cisplatinom in 5-fluorouracilom (navedeni so klinično pomembni, z zdravljenjem povezani, neželeni učinki).
300 gastric adenocarcinoma patients (221 patients in the phase III part of the study and 79 patients in the phase II part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).
Med 300 bolniki (221 bolnikov v III. fazi študije in 79 bolnikov v II. fazi študije), ki so jih zdravili z docetakselom v kombinaciji s cisplatinom in 5-fluorouracilom v študiji raka želodca, je bilo 74 bolnikov starih 65 let ali več, 4 pa so bili stari 75 let ali več.
300 IU/0.36 mL
150 i.e./0,18 ml
300 IU/0.50 ml
300 i.e./0,50 ml
300 mcg/m2 intramuscularly (mcg/kg) (ml)
300 mikrogramov/m2 intramsukularno (mikrogramov/kg) (ml)
300 mg (30 ml) once daily
300 mg (30 ml) enkrat na dan
300 mg at week 2; then 300 mg every 2 weeks
300 mg 2. teden; nato 300 mg vsaka 2 tedna
300 mg at week 2; then 300 mg every 2 weeks
300 mg 2. teden; nato 300 mg vsake 2 tedna
300 mg at week 2; then 300 mg every 3 weeks
300 mg 2. teden; nato 300 mg vsake 3 tedne
300 mg dose - Use 3 vials (15 ml total, 5 ml per vial):
Odmerek 300 mg – Uporabite 3 viale (skupaj 15 ml, 5 ml na vialo):
300 mg dose - Use 3 x 100 mg/5 ml vials (15 ml total, 5 ml per vial):
Odmerek 300 mg – Uporabite 3 viale s 100 mg/5 ml (skupaj 15 ml, 5 ml na vialo):
300 mg film-coated tablets
300 mg filmsko obložene tablete
300 mg in randomised, double-blind and active-controlled clinical trials of up to 24 weeks’ duration.
300 mg v randomiziranih, dvojno slepih, aktivno kontroliranih študijah, ki so trajale do 24 tednov.
300 mg once daily
25 mg enkrat na dan
300 mg once daily
300 mg enkrat na dan
300 mg once daily (Day 1 300 mg twice daily)*
300 mg enkrat na dan (1. dan 300 mg dvakrat na dan)
300 mg once daily.
300 mg enkrat na dan.
300 mg once daily.
400/100 mg dvakrat na dan.
300 mg once daily†
300 mg enkrat na dan
300 mg per day
300 mg na dan (enkrat na dan).
300 mg powder for concentrate
300 mg praška za koncentrat
300 mg prednisolone
300 mg prednizolona
300 mg QD (co-administered with voriconazole 400 mg BID)*
300 mg QD (co-administered with vorikonazol 400 mg BID)
300 mg QD (co-administered with voriconazole 400 mg BID)*
300 mg QD (sočasno uporabljan s 400 mg vorikonazola BID)
300 mg QD (co-administered with voriconazole 400 mg BID)*
400 mg vorikonazola BID)
300 mg QD (coadministered with voriconazole 350 mg BID)*
300 mg QD (sočasno uporabljan s 350 mg vorikonazola BID)
300 mg QD (coadministered with voriconazole 400 mg BID)*
300 mg QD (sočasno uporabljan s 400 mg vorikonazola BID)
300 mg single dose
300 mg enkratni odmerek
300 mg tablets and/or
mg tablet in/ali 500-mg
300 mg TID (coadministered with voriconazole 400 mg
300 mg TID (sočasno uporabljana z enkratnim
300 mg twice daily
300 mg dvakrat dnevno
300 mg twice daily and
dvakrat na dan (marivarok 300 mg
300 mg twice daily and
dvakrat na dan)
300 mg twice daily group, 98.7% (95% CI: 97.1-100%) in the nilotinib 400 mg twice daily group and 97.0% (95% CI: 94.7-99.4%) in the imatinib 400 mg once daily group.
400 mg dvakrat dnevno in 97,0 % (95-odstotni IZ: 94,7-99,4 %) v skupini z imatinibom 400 mg enkrat na dan.
300 mg twice daily in newly diagnosed patients with CML in the chronic phase,
300 mg dvakrat dnevno pri bolnikih z novo odkrito KML v kronični fazi,